These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38278960)

  • 1. Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
    Flygt H; Söderlund S; Richter J; Saussele S; Koskenvesa P; Stenke L; Mustjoki S; Dimitrijevic A; Stentoft J; Majeed W; Roy L; Wolf D; Dreimane A; Gjertsen BT; Gedde-Dahl T; Ahlstrand E; Markevärn B; Hjorth-Hansen H; Janssen J; Olsson-Strömberg U
    Leukemia; 2024 Apr; 38(4):781-787. PubMed ID: 38278960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
    Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
    Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
    Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group.
    Yamaguchi H; Takezako N; Ohashi K; Oba K; Kumagai T; Kozai Y; Wakita H; Yamamoto K; Fujita A; Igarashi T; Yoshida C; Ohyashiki K; Okamoto S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Hematol; 2020 Mar; 111(3):401-408. PubMed ID: 31894533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
    Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience.
    Ureshino H; Kamachi K; Nishioka A; Okamoto S; Katsuya H; Yoshimura M; Kubota Y; Ando T; Kimura S
    Hematol Oncol; 2021 Oct; 39(4):549-557. PubMed ID: 34117654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
    Perusini MA; Novitzky-Basso I; Atenafu EG; Forrest D; Bence-Bruckler I; Savoie L; Keating MM; Busque L; Delage R; Xenocostas A; Liew E; Laneuville P; Paulson K; Stockley T; Lipton JH; Leber B; Kim DDH
    Br J Haematol; 2023 Dec; 203(5):781-791. PubMed ID: 37697469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.
    Okada M; Imagawa J; Tanaka H; Nakamae H; Hino M; Murai K; Ishida Y; Kumagai T; Sato S; Ohashi K; Sakamaki H; Wakita H; Uoshima N; Nakagawa Y; Minami Y; Ogasawara M; Takeoka T; Akasaka H; Utsumi T; Uike N; Sato T; Ando S; Usuki K; Mizuta S; Hashino S; Nomura T; Shikami M; Fukutani H; Ohe Y; Kosugi H; Shibayama H; Maeda Y; Fukushima T; Yamazaki H; Tsubaki K; Kukita T; Adachi Y; Nataduka T; Sakoda H; Yokoyama H; Okamoto T; Shirasugi Y; Onishi Y; Nohgawa M; Yoshihara S; Morita S; Sakamoto J; Kimura S;
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):353-360.e1. PubMed ID: 29610029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis the influence factors of treatment free remission outcome with chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitors].
    Zhao HF; Zhang Y; Dang LX; Liang JL; Chen SX; Guo Z; Li YL; Zu RR; Gui XD; Wei YP; Song Y
    Zhonghua Yi Xue Za Zhi; 2022 May; 102(20):1523-1529. PubMed ID: 35692068
    [No Abstract]   [Full Text] [Related]  

  • 10. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
    Rea D; Nicolini FE; Tulliez M; Guilhot F; Guilhot J; Guerci-Bresler A; Gardembas M; Coiteux V; Guillerm G; Legros L; Etienne G; Pignon JM; Villemagne B; Escoffre-Barbe M; Ianotto JC; Charbonnier A; Johnson-Ansah H; Noel MP; Rousselot P; Mahon FX;
    Blood; 2017 Feb; 129(7):846-854. PubMed ID: 27932374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
    Cortes J; Rea D; Lipton JH
    Am J Hematol; 2019 Mar; 94(3):346-357. PubMed ID: 30394563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
    Iino M; Yamamoto T; Sakamoto Y
    Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
    Shah NP; García-Gutiérrez V; Jiménez-Velasco A; Larson SM; Saussele S; Rea D; Mahon FX; Levy MY; Gómez-Casares MT; Mauro MJ; Sy O; Martin-Regueira P; Lipton JH
    Br J Haematol; 2023 Sep; 202(5):942-952. PubMed ID: 37246588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.
    Kumagai T; Nakaseko C; Nishiwaki K; Yoshida C; Ohashi K; Takezako N; Takano H; Kouzai Y; Murase T; Matsue K; Morita S; Sakamoto J; Wakita H; Sakamaki H; Inokuchi K;
    Cancer Sci; 2020 Aug; 111(8):2923-2934. PubMed ID: 32614159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia.
    Ureshino H; Kamachi K; Kimura S
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e138-e141. PubMed ID: 38195325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-Free Remission in Real-World Chronic Myeloid Leukemia Patients: Insights from German Hematology Practices.
    Dengler J; Tesch H; Jentsch-Ullrich K; Gerhardt A; Schulte C; Lipke J; Löwe G; Kiani A
    Acta Haematol; 2022; 145(6):603-610. PubMed ID: 35908542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
    Shah NP; García-Gutiérrez V; Jiménez-Velasco A; Larson S; Saussele S; Rea D; Mahon FX; Levy MY; Gómez-Casares MT; Pane F; Nicolini FE; Mauro MJ; Sy O; Martin-Regueira P; Lipton JH
    Leuk Lymphoma; 2020 Mar; 61(3):650-659. PubMed ID: 31647335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.
    Yoshida C; Yamaguchi H; Doki N; Murai K; Iino M; Hatta Y; Onizuka M; Yokose N; Fujimaki K; Hagihara M; Oshikawa G; Murayama K; Kumagai T; Kimura S; Najima Y; Iriyama N; Tsutsumi I; Oba K; Kojima H; Sakamaki H; Inokuchi K;
    Int J Hematol; 2023 May; 117(5):694-705. PubMed ID: 36739328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.